Project Number 5P01AG000538-38 Agency/Funding Organization NIA Funding Year 2018 View Full Project Details for PICALM, Oligomeric Abeta and Inflammation in Neurovascular Pathogenesis in AD Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 9. Immunity and Inflammation h. Other Researcher and Organization Principal Investigator CRIBBS, DAVID HASTINGS Principal Investigator First Name DAVID Principal Investigator Last Name CRIBBS Awardee Organization UNIVERSITY OF CALIFORNIA IRVINE Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-11-066: NIA PROGRAM PROJECT APPLICATIONS (P01) FY Overall Cost $264,325 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official WISE, BRADLEY C Related Resources Repository [AlzPED] HuCNS-SC Human NSCs Fail to Differentiate, Form Ectopic Clusters, and Provide No Cognitive Benefits in a Transgenic Model of Alzheimer's Disease. [AlzPED] Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization. [AlzPED] Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. [AlzPED] Low Concentrations of Anti-Abeta Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology [AlzPED] Reductions in Aβ-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation [AlzPED] Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.
